NCT05118243

Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance

University of Helsinki·ClinicalTrials.gov·otherActive, not recruiting
View on ClinicalTrials.gov
Study focus
Drug/Device/Intervention
Control cracker
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Helsinki
Location
Helsinki, Finland
Timeline & enrollment
Phase
N/A
Start date
Sep 06, 2021
End date
Dec 01, 2022
Enrollment
20 participants
Primary outcome

The intensity of stomach pain measured by a visual analogue scale,The intensity of stomach cramps measured by a visual analogue scale,The intensity of bloating measured by a visual analogue scale,The intensity of flatulence measured by a visual analogue scale,The intensity of stomach noise measured by a visual analogue scale,The intensity of nausea measured by a visual analogue scale,The intensity of heartburn measured by a visual analogue scale,The intensity of an unpleasant feeling in the upper abdomen or the feeling of feeling full fast related to eating measured by a visual analogue scale,The intensity of a sudden need to defecate measured by a visual analogue scale,The composition of gut microbiota analyzed from fecal samples using 16S rRNA amplicon sequencing

Summary

The aim of this study is to investigate the effects of enzymatic treatment to reduce GOS
 (galactooligosaccharides) in legume-based crackers in IBS (irritable bowel syndrome) persons.
 The crackers are pea-based: the control crackers contain high amounts of GOS, while the
 enzymatically treated crackers contain a minimal amount of GOS. The participants will eat
 each type of cracker for three days (daily dose of 12 crackers) and report their gut symptoms
 (e.g. flatulence, stomach pain, bloating) by using a mobile app. There is a washout period of
 four days between the different crackers. In addition, the participants will keep food
 records on the cracker eating days as well as collect five fecal samples during the study.
 The participants will also report their physical activity and the number of defecations on
 each day. The study is carried out in a double-blinded crossover setting.

ICD-10 classifications
Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndromeIrritable bowel syndrome with predominant diarrhoea [IBS-D]Irritable bowel syndrome with mixed bowel habits [IBS-M]Other and unspecified irritable bowel syndrome
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05118243
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05118243 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Helsinki and is currently Active, not recruiting. The study focuses on IBS - Irritable Bowel Syndrome. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.